Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY 10.6
(-0.19%)
CNY 10.6
(-0.19%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 859.39 Million CNY | 179.34% |
| 2022 | 386.23 Million CNY | -56.98% |
| 2021 | 897.72 Million CNY | -26.35% |
| 2020 | 1.21 Billion CNY | -3.85% |
| 2019 | 1.26 Billion CNY | 0.54% |
| 2018 | 1.26 Billion CNY | 18.63% |
| 2017 | 1.06 Billion CNY | 2.93% |
| 2016 | 1.03 Billion CNY | 18.43% |
| 2015 | 871.85 Million CNY | 99.69% |
| 2014 | 436.61 Million CNY | 20.11% |
| 2013 | 363.51 Million CNY | 9.72% |
| 2012 | 331.3 Million CNY | 41.64% |
| 2011 | 233.9 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 179.65 Million CNY | -29.42% |
| 2024 Q2 | 143.49 Million CNY | -20.13% |
| 2024 Q3 | 130.74 Million CNY | 21.78% |
| 2023 Q1 | 318.4 Million CNY | 224.25% |
| 2023 Q4 | 254.52 Million CNY | 5.09% |
| 2023 Q3 | 242.19 Million CNY | -8.17% |
| 2023 Q2 | 263.75 Million CNY | -17.16% |
| 2023 FY | 1.07 Billion CNY | 179.34% |
| 2022 Q4 | -256.26 Million CNY | -208.38% |
| 2022 Q2 | 219.86 Million CNY | 18.1% |
| 2022 Q3 | 236.45 Million CNY | 7.54% |
| 2022 FY | 386.23 Million CNY | -56.98% |
| 2022 Q1 | 186.17 Million CNY | 63.13% |
| 2021 Q1 | 200.33 Million CNY | -44.59% |
| 2021 Q3 | 251.81 Million CNY | -24.03% |
| 2021 Q4 | 114.12 Million CNY | -54.68% |
| 2021 FY | 897.72 Million CNY | -26.35% |
| 2021 Q2 | 331.45 Million CNY | 65.45% |
| 2020 Q2 | 348.56 Million CNY | 53.43% |
| 2020 Q4 | 361.53 Million CNY | 28.4% |
| 2020 Q1 | 227.18 Million CNY | -44.94% |
| 2020 Q3 | 281.55 Million CNY | -19.22% |
| 2020 FY | 1.21 Billion CNY | -3.85% |
| 2019 FY | 1.26 Billion CNY | 0.54% |
| 2019 Q1 | 349.02 Million CNY | 14.28% |
| 2019 Q2 | 216.76 Million CNY | -37.89% |
| 2019 Q4 | 412.57 Million CNY | 42.63% |
| 2019 Q3 | 289.26 Million CNY | 33.45% |
| 2018 FY | 1.26 Billion CNY | 18.63% |
| 2018 Q4 | 305.41 Million CNY | -7.7% |
| 2018 Q3 | 330.89 Million CNY | -11.04% |
| 2018 Q2 | 371.97 Million CNY | 47.26% |
| 2018 Q1 | 252.59 Million CNY | -40.02% |
| 2017 Q1 | 178.2 Million CNY | -64.37% |
| 2017 FY | 1.06 Billion CNY | 2.93% |
| 2017 Q4 | 421.11 Million CNY | 117.75% |
| 2017 Q3 | 193.39 Million CNY | -28.4% |
| 2017 Q2 | 270.11 Million CNY | 51.57% |
| 2016 FY | 1.03 Billion CNY | 18.43% |
| 2016 Q4 | 500.19 Million CNY | 122.81% |
| 2016 Q3 | 224.49 Million CNY | 24.65% |
| 2016 Q2 | 180.09 Million CNY | 41.63% |
| 2016 Q1 | 127.15 Million CNY | -56.1% |
| 2015 Q1 | 90.61 Million CNY | -47.59% |
| 2015 Q2 | 160.46 Million CNY | 77.1% |
| 2015 FY | 871.85 Million CNY | 99.69% |
| 2015 Q4 | 289.67 Million CNY | -12.51% |
| 2015 Q3 | 331.09 Million CNY | 106.33% |
| 2014 Q3 | 95.14 Million CNY | -9.51% |
| 2014 FY | 436.61 Million CNY | 20.11% |
| 2014 Q4 | 172.88 Million CNY | 81.71% |
| 2014 Q2 | 105.14 Million CNY | 65.73% |
| 2014 Q1 | 63.44 Million CNY | 0.0% |
| 2013 FY | 363.51 Million CNY | 9.72% |
| 2012 FY | 331.3 Million CNY | 41.64% |
| 2011 FY | 233.9 Million CNY | 0.0% |